Strata Skin Sciences (SSKN)
(Delayed Data from NSDQ)
$3.01 USD
-0.25 (-7.67%)
Updated Sep 13, 2024 03:56 PM ET
After-Market: $3.20 +0.19 (6.31%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Strata Skin Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 7 | 13 | 18 | 16 |
Receivables | 4 | 4 | 3 | 3 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 6 | 3 | 3 | 3 |
Other Current Assets | 0 | 1 | 0 | 0 | 1 |
Total Current Assets | 16 | 18 | 20 | 25 | 24 |
Net Property & Equipment | 12 | 8 | 7 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 14 | 26 | 19 | 15 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 42 | 52 | 47 | 47 | 47 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 7 | 7 |
Accounts Payable | 3 | 3 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 7 | 6 | 5 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 3 | 2 | 3 |
Total Current Liabilities | 12 | 13 | 13 | 19 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 15 | 7 | 7 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 8 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 30 | 21 | 21 | 19 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 251 | 249 | 247 | 245 | 243 |
Retained Earnings | -238 | -227 | -222 | -219 | -215 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 22 | 25 | 26 | 29 |
Total Liabilities & Shareholder's Equity | 42 | 52 | 47 | 47 | 47 |
Total Common Equity | 13 | 22 | 25 | 26 | 29 |
Shares Outstanding | 3.40 | 3.40 | 3.40 | 3.30 | 3.20 |
Book Value Per Share | 3.73 | 6.42 | 7.47 | 7.85 | 8.95 |
Fiscal Year End for Strata Skin Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 7 | 8 | 8 | 10 |
Receivables | 4 | 4 | 4 | 5 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 6 | 6 |
Other Current Assets | 0 | 0 | 0 | 0 | 1 |
Total Current Assets | 14 | 13 | 16 | 20 | 21 |
Net Property & Equipment | 11 | 12 | 12 | 8 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 13 | 13 | 14 | 18 | 25 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 40 | 40 | 42 | 47 | 55 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 6 | 6 | 6 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 3 | 3 |
Total Current Liabilities | 12 | 13 | 12 | 12 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 15 | 15 | 15 | 15 | 15 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 3 | 8 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 31 | 29 | 31 | 38 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 251 | 251 | 251 | 250 | 250 |
Retained Earnings | -242 | -241 | -238 | -234 | -233 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 9 | 13 | 16 | 17 |
Total Liabilities & Shareholder's Equity | 40 | 40 | 42 | 47 | 55 |
Total Common Equity | 10 | 9 | 13 | 16 | 17 |
Shares Outstanding | 3.50 | 3.50 | 3.40 | 3.40 | 3.40 |
Book Value Per Share | 2.71 | 2.69 | 3.73 | 4.76 | 4.97 |